Why Is Everyone Talking About Moderna Stock?
_0.png?locale=de){kind=logo}
When Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced last week that the vaccine candidate they had developed was 90% effective at preventing COVID-19 infection, the market (and everyone else) celebrated. This seemed like a high bar to clear for other companies working on a vaccine to fight the novel coronavirus. But now, another company using the same gene-based approach is saying "not so fast" to those who last week thought the vaccine race had been won.
Moderna (NASDAQ: MRNA) just released preliminary results for its 30,000-person study of the company's two-dose vaccine using messenger RNA (mRNA) technology, similar to the candidate from Pfizer and BioNTech. The result is giving billions of people hope that there is a light at the end of the pandemic tunnel.
Image source: Getty Images.
Source Fool.com
